KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

被引：0
|
作者：
Atkins, Michael B.
Carlino, Matteo S.
Hill, Andrew G.
McNeil, Catriona M.
Long, Georgina V.
Atkinson, Victoria
Cebon, Jonathan S.
Jameson, Michael B.
Hwu, Wen-Jen
Thompson, John A.
Anderson, James
Moreno, Blanca Homet
Ibrahim, Nageatte
Ribas, Antoni
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT065
引用
收藏
页数：2
相关论文
共 50 条
  • [21] 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma
    Robert, Caroline
    Schachter, Jacob
    Long, Georgina V.
    Arance, Ana
    Grob, Jean-Jacques
    Mortier, Laurent
    Daud, Adil
    Carlino, Matteo S.
    McNeil, Catriona
    Lotem, Michal
    Larkin, James
    Lorigan, Paul
    Neyns, Bart
    Blank, Christian U.
    Hamid, Omid
    Petrella, Teresa M.
    Anderson, James
    Krepler, Clemens
    Diede, Scott J.
    Ribas, Antoni
    CANCER RESEARCH, 2019, 79 (13)
  • [22] 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
    Long, Georgina V.
    Schachter, Jacob
    Ribas, Antoni
    Arance, Ana M.
    Grob, Jean-Jacques
    Mortier, Laurent
    Daud, Adil
    Carlino, Matteo S.
    McNeil, Catriona M.
    Lotem, Michal
    Larkin, James M. G.
    Lorigan, Paul
    Neyns, Bart
    Blank, Christian U.
    Petrella, Teresa M.
    Hamid, Omid
    Anderson, James
    Krepler, Clemens
    Ibrahim, Nageatte
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma
    Williamson, Julie
    Fadlullah, Muhammad Zaki Hidayatullah
    Kovacsovics, Magdalena
    Gibson, Berit
    Erickson-Wayman, Alyssa
    Jamison, Debra
    Sageser, Daniel S.
    Swami, Umang
    Jeter, Joanne M.
    Bowles, Tawnya Lynn
    Cannon, Donald Maurice
    Ben Haaland
    Schroeder, Joyce
    McPherson, Jordan P.
    Hyngstrom, John Robert
    Tan, Aik-choon
    Hu-Lieskovan, Siwen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
    Hamid, O.
    Puzanov, I.
    Dummer, R.
    Schachter, J.
    Daud, A.
    Schadendorf, D.
    Blank, C.
    Cranmer, L. D.
    Robert, C.
    Pavlick, A. C.
    Gonzalez, R.
    Hodi, F. S.
    Ascierto, P. A.
    Salama, A.
    Margolin, K. A.
    Gangadhar, T. C.
    Wei, Z.
    Ebbinghaus, S. W.
    Ibrahim, N.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
    Carlino, Matteo S.
    Menzies, Alexander M.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Fitzharris, Bernard M.
    McNeil, Catriona M.
    Hill, Andrew G.
    Ribas, Antoni
    Atkins, Michael B.
    Thompson, John A.
    Hwu, Wen-Jen
    Hodi, F. Stephen
    Guminski, Alexander D.
    Kefford, Richard
    Wu, Haiyan
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Long, Georgina, V
    CLINICAL CANCER RESEARCH, 2020, 26 (19) : 5086 - 5091
  • [26] Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.
    Hodi, F. Stephen
    Lee, Sandra J.
    McDermott, David F.
    Rao, Uma N. M.
    Butterfield, Lisa H.
    Tarhini, Ahmad A.
    Leming, Philip D.
    Puzanov, Igor
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [27] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [28] Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608
    Hodi, F. Stephen
    Lee, Sandra J.
    McDermott, David F.
    Rao, Uma N. M.
    Butterfield, Lisa H.
    Tarhini, Ahmad A.
    Leming, Philip D.
    Puzanov, Igor
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
    Shaikh, Saba
    Zang, Yan
    Hanmer, Janel
    Wang, Hong
    Lin, Yan
    Davar, Diwakar
    Zarour, Hassane M.
    Kirkwood, John M.
    Najjar, Yana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.
    Long, Georgina V.
    Schachter, Jacob
    Arance, Ana
    Grob, Jean-Jacques
    Mortier, Laurent
    Daud, Adil
    Carlino, Matteo S.
    Ribas, Antoni
    McNeil, Catriona M.
    Lotem, Michal
    Larkin, James M. G.
    Lorigan, Paul
    Neyns, Bart
    Blank, Christian U.
    Petrella, Teresa M.
    Hamid, Omid
    Jensen, Erin
    Krepler, Clemens
    Diede, Scott J.
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345